Lupus Foundation’s umbilical cord cell therapy trial misses primary endpoint
A Phase II trial of an umbilical cord stem cell-based therapy as a treatment for adults with active systemic lupus…
A Phase II trial of an umbilical cord stem cell-based therapy as a treatment for adults with active systemic lupus…
At a time when innovative medicines with new mechanisms of action (MOA) are growing at pace thanks to artificial intelligence…
Artificial intelligence (AI) is being used in all areas of clinical trials, from patient recruitment to data analysis, including protocol…
While Priavoid’s oral Alzheimer’s disease drug has been shown to be safe and tolerable, it failed to have a significant…
Novo’s subcutaneous Wegovy (semaglutide) has reduced body mass index (BMI) by at least 10% in 80% of children with obesity…
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is launching a Women’s Health Programme to boost female participation in…
CG Oncology’s adenovirus-based oncolytic viral immunotherapy has shown significant improvements in a Phase III non-muscle invasive bladder cancer (NMIBC) trial.…
Aclaris Therapeutics’ monoclonal antibody (mAb) failed to show benefit in a Phase II atopic dermatitis (AD) trial. The ADMIRATION trial…
Aravax’s Phase II peanut allergy trial met its primary endpoint, with younger paediatric patients able to better tolerate peanuts after…
Beeline Medicines has unveiled detailed data behind its Bristol Myers Squibb (BMS)- licenced drug afimetoran, which showed it provided statistically…